MEET MANOUSH #2: the Tipping Point
In its last Quarter ISAB reported a 722% increase in revenues compared to the same time last year. How will it keep up the momentum? CEO Manoush Masarrat…
In its last Quarter ISAB reported a 722% increase in revenues compared to the same time last year. How will it keep up the momentum? CEO Manoush Masarrat…
Will Coronavirus have any long-term impact on ISAB? Is ISAB currently carrying out any Contract Research on Coronavirus? Will there be a ’new normal’ in the inhalation research…
Inhalation Sciences recently shipped two newly commercialized DissolvIt® units to two customers—in just one week. What are the new and optimized features in this final market version that help…
Den 16:e september tillträdde Manoush Masarrat som ny VD på Inhalation Sciences Sweden AB. Med 15 års erfarenhet av ledande positioner inom MedTech och 10 månader som ISAB-styrelseledamot,…
On 16th September Manoush Masarrat stepped up as new CEO of Inhalation Sciences. With 15 years’ Medtech leadership experience and 10 months as an ISAB Board member, how…
ISAB’s new nebulizer feature delivers the stability, precision and control of a dry powder aerosol—from a liquid solution. Developed by popular demand, four nebulizer modules have already been…
From Austria to Sweden to California to the UK: October has been an intensive month for PreciseInhale®, ISAB’s flagship product. It has been spotlighted by senior ISAB clients…
From Austria to Sweden to California to the UK: October has been an intensive month for PreciseInhale® , ISAB’s flagship product. It has been spotlighted by senior ISAB…
From Austria to Sweden to California to the UK: October has been an intensive month for PreciseInhale®, ISAB’s flagship product. It has been spotlighted by senior ISAB clients…
ISAB is co-sponsoring a Special Summit “How to succeed with the FDA”, headlined by US regulatory pharma expert Dr Ann Rose, CEO of ViCRO. ISAB Chairman Fredrik Sjövall…